Free Trial
NASDAQ:RANI

Rani Therapeutics Q1 2024 Earnings Report

Rani Therapeutics logo
$1.08 0.00 (0.00%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$1.09 +0.01 (+1.02%)
As of 05/5/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Rani Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rani Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 6, 2024
Conference Call Time
7:00AM ET

Rani Therapeutics Earnings Headlines

Rani Therapeutics (RANI) Expected to Announce Earnings on Monday
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street
RANI: 2024 Financial Results
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

View Rani Therapeutics Profile

More Earnings Resources from MarketBeat